Analysts expect iRadimed Corporation (NASDAQ:IRMD) to report $0.06 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for iRadimed’s earnings. iRadimed reported earnings per share of $0.11 during the same quarter last year, which suggests a negative year over year growth rate of 45.5%. The firm is expected to issue its next quarterly earnings report on Monday, February 5th.

According to Zacks, analysts expect that iRadimed will report full-year earnings of $0.19 per share for the current financial year. For the next fiscal year, analysts expect that the business will report earnings of $0.25 per share. Zacks’ EPS calculations are an average based on a survey of research analysts that cover iRadimed.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.35. iRadimed had a return on equity of 4.58% and a net margin of 6.51%. The company had revenue of $5.69 million for the quarter, compared to the consensus estimate of $5.60 million. During the same period in the previous year, the business earned $0.14 EPS. iRadimed’s revenue for the quarter was down 25.9% compared to the same quarter last year.

IRMD has been the subject of a number of research analyst reports. Zacks Investment Research downgraded iRadimed from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. ValuEngine upgraded iRadimed from a “sell” rating to a “hold” rating in a report on Friday, October 6th. Roth Capital started coverage on iRadimed in a research report on Tuesday, October 31st. They set a “buy” rating and a $16.00 price objective for the company. Finally, Credit Suisse Group started coverage on iRadimed in a research report on Monday, November 27th. They set a “buy” rating and a $19.00 price objective for the company. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $15.33.

Shares of iRadimed (IRMD) remained flat at $$13.60 during midday trading on Wednesday. 7,702 shares of the company traded hands, compared to its average volume of 39,761. iRadimed has a 12-month low of $7.85 and a 12-month high of $15.00. The firm has a market capitalization of $143.02, a P/E ratio of 104.23 and a beta of 1.61.

In other iRadimed news, Director Monty K. Allen sold 1,898 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $13.95, for a total transaction of $26,477.10. Following the completion of the transaction, the director now owns 9,062 shares in the company, valued at approximately $126,414.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 60.10% of the company’s stock.

A number of hedge funds have recently made changes to their positions in IRMD. Ameriprise Financial Inc. lifted its holdings in shares of iRadimed by 32.9% in the third quarter. Ameriprise Financial Inc. now owns 456,810 shares of the medical equipment provider’s stock valued at $4,386,000 after buying an additional 113,190 shares during the period. Connors Investor Services Inc. lifted its holdings in shares of iRadimed by 10.0% in the second quarter. Connors Investor Services Inc. now owns 33,000 shares of the medical equipment provider’s stock valued at $284,000 after buying an additional 3,000 shares during the period. Citigroup Inc. lifted its holdings in shares of iRadimed by 50.8% in the second quarter. Citigroup Inc. now owns 16,082 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 5,418 shares during the period. Menta Capital LLC lifted its holdings in shares of iRadimed by 5.7% in the second quarter. Menta Capital LLC now owns 70,476 shares of the medical equipment provider’s stock valued at $606,000 after buying an additional 3,823 shares during the period. Finally, Neuberger Berman Group LLC lifted its holdings in shares of iRadimed by 23.3% in the second quarter. Neuberger Berman Group LLC now owns 18,500 shares of the medical equipment provider’s stock valued at $159,000 after buying an additional 3,500 shares during the period. Institutional investors own 13.83% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect iRadimed Corporation (IRMD) Will Post Earnings of $0.06 Per Share” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/06/zacks-analysts-expect-iradimed-corporation-irmd-will-post-earnings-of-0-06-per-share.html.

About iRadimed

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get a free copy of the Zacks research report on iRadimed (IRMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related stocks with our FREE daily email newsletter.